Is tuberculin skin testing useful to diagnose latent tuberculosis in BCG-vaccinated children?

International Journal of Epidemiology

Volumn 35, Issue 6, 2006, Pages 1447-1454

  García Sancho, Ma Cecilia ^a,b   García García, Lourdes ^a,f   Jiménez Corona, Ma Eugenia ^a   Palacios Martínez, Manuel ^a   Ferreyra Reyes, Leticia D ^a   Canizales Quintero, Sergio ^a   Cano Arellano, Bulmaro ^a   Ponce de León, Alfredo ^c   Sifuentes Osornio, José ^c   Small, Peter ^e   DeRiemer, Kathryn ^d  

^a INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^b INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^c INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e BILL AND MELINDA GATES FOUNDATION   (United States)

^f Tuberculosis Unit   (Mexico)

Author keywords

Bacille Calmette Gu rin (BCG) vaccine; Latent infection; Mycobacterium tuberculosis; Tuberculin skin test

Indexed keywords

BCG VACCINE;

EPIDEMIOLOGY; INFECTIOUS DISEASE; TUBERCULOSIS; VACCINE;

ADOLESCENT; AGE DISTRIBUTION; ARTICLE; BCG VACCINATION; CHILD; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC VALUE; ELEMENTARY STUDENT; EXPOSURE VARIABLE; FEMALE; HUMAN; INCIDENCE; INJECTION SITE SCAR; MAJOR CLINICAL STUDY; MALE; MEXICO; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; QUESTIONNAIRE; RISK ASSESSMENT; SAMPLING; TUBERCULIN TEST; TUBERCULOSIS;

MEXICO [NORTH AMERICA]; NORTH AMERICA; PICO DE ORIZABA; VERACRUZ;

MYCOBACTERIUM TUBERCULOSIS;

EID: 33846645435     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dyl213     Document Type: Article

References (43)

1. Arnadottir T, Rieder HL, Trebucq A, Waaler HT. Guidelines for conducting tuberculin skin test surveys in high prevalence countries. Tuber Lung Dis 1996;77(Supp.1):1-19
2. Lee E, Holzman RS. Evolution and current use of the tuberculin test. Clin Infect Dis 2002;34:365-70.
3. Sepulveda RL, Burr C, Ferrer X, Sorensen RU. Booster effect of tuberculin testing in healthy 6-year-old school children vaccinated with Bacillus Calmette- Guerin at birth in Santiago, Chile. Pediatr Infect Dis J 1988;7:578-81.
4. Menzies R, Vissandjee B. Effect of bacille Calmette-Guerin vaccination on tuberculin reactivity. Am Rev Respir Dis 1992;145:621-25.
5. Modificación a la Norma Oficial Mexicana NOM-006-SSA2-1993. Para la prevención y control de la tuberculosis en la atención primaria a la salud. Diario Oficial de la Federación, 2000, octubre 31.
6. Instituto Nacional de Estadística, Geografía e Informática. Estados Unidos Mexicanos. XII Censo General de Población y Vivienda 2000. Resultados preliminares. Aguascalientes; Ags; Instituto Nacional de Estadística, Geografía e Informática, 2000.
7. Dirección General de Epidemiología. Sistema Único de Información. Secretaría de Salud 2001;18:4-7.
8. Norma Oficial Mexicana NOM-036-SSA2-2002, Prevención y control de enfermedades. Aplicación de vacunas, toxoides, sueros, antitoxinas e inmunoglobulinas en el humano. Disponible en: http://www.salud.gob.mx/unidades/cdi/nom/036ssa202.html
9. Pouchot J, Grasland A, Collet C et al. Reliability of tuberculin skin test measurement. Ann Intern Med 1997;126:210-14.
10. Yaffee RA. SUDAAN 7: Statistical Analysis Software for Complex Sample Designs. Research Triangle Institute in Cary, NC, USA 1997.)
11. Manual Update. Section 3.6 Computation of Design Effects. SUDAAN 8.01. Volume I. December 17, 2001.
12. Sullivan KM, Gorstein J. ANTHRO: Software for Calculating Pediatric Anthropometry, (ed. 1.01). Atlanta, GA: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, the National Center of Chronic Disease Prevention and Health Promotion, Division of Nutrition, Nutrition Unit; and the World Health Organization, Geneva, Switzerland, 1990.
13. Shah BV, Barnewell BG, Hunt PN et al. SUDAAN User's Manual, Release 5.50. Research Triangle Park, NC: Research Triangle Institute, 1991.
14. Lienhardt C, Sillah J, Fielding K et al. Risk factors for tuberculosis infection in children in contact with infectious tuberculosis cases in The Gambia, West Africa. Pediatrics 2003;111:e608-14.
15. Lienhardt C, Fielding K, Sillah J et al. Risk factors for tuberculosis infection in sub-Saharan Africa: A contact study in The Gambia. Am J Respir Crit Care Med 2003;168:448-55.
16. Lockman S, Tappero JW, Kenyon TA et al. Tuberculin reactivity in a pediatric population with high BCG vaccination coverage. Int J Tuberc Lung Dis 1999;3:23-30.
17. Rathi SK, Akhtar S, Rahbar MH, Azam SI. Prevalence and risk factors associated with tuberculin skin test positivity among household contacts of smear-positive pulmonary tuberculosis cases in Umerkot, Pakistan. Int J Tuberc Lung Dis 2002;6:851-57.
18. Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol 1974;99:131-38.
19. Olender S, Saito M, Apgar J et al. Low prevalence and increased household clustering of Mycobacterium tuberculosis infection in high altitude villages in Peru. Am J Trop Med Hyg 2003;68:721-27.
20. Gerald LB, Tang S, Bruce F et al. A decision three for tuberculosis contact investigation. Am J Respir Crit Care Med 2002;166:1122-27.
21. Ormerod LP, Garnett JM. Tuberculin skin reactivity four years after neonatal BCG vaccination. Arch Dis Child 1992;67:530-31.
22. Bozaykut A, Ipek IO, Ozkars MY et al. Effect of BCG vaccine on tuberculin skin tests in 1-6-year-old children. Acta Paediatr 2002;91:235-38.
23. Miret-Cuadras P, Pina-Gutierrez JM, Juncosa S. Tuberculin reactivity in Bacillus Calmette-Guérin vaccinated subjects. Int J Tuber Lung Dis 1996;77:52-58.
24. Rosenthal SR, Loewinsohn E, Graham ML et al. BCG vaccination against tuberculosis in Chicago. Pediatrics 1961;28:622-41.
25. Haro M, Vizcaya M, Andicoberry MJ, Grupo de Estudio de Contactos de la Sección de Neumologia del Hospital General de Albacete. Trends in the prevalence of tuberculosis among six-year-olds in Albacete (Spain). Arch Bronconeumol 2002;38:221-25.
26. Kröger L, Katila ML, Korppi M et al. Rapid decrease in tuberculin skin test reactivity at preschool age after newborn vaccination. Acta Paediatr 1992;81:678-81.
27. Lifschitz M. The value of the tuberculin skin test as a screening test for tuberculosis among BCG-vaccinated children. Pediatrics 1965; 36:624-27.
28. Perez Stable EJ, Slutkin G, Paz AE, Hopewell PC. Tuberculin reactivity in United States and foreign-born Latinos: Results of a community-based screening program. Am J Public Health 1986; 76:643-46.
29. Vall Mayans M, Besora R, Estabanell A et al. High rates of tuberculosis infection among children from Ciutat Vella District, Barcelona, 1996-1997. Int J Tuberc Lung Dis 2001;5:92-95.
30. Almeida LM, Barbieri MA, Da Paixao AC et al. Use of purified protein derivative to assess the risk of infection in children in close contact with adults with tuberculosis in a population with high Calmette-Guérin bacillus coverage. Pediatr Infect Dis J 2001;20: 1061-65.
31. Young TK, Mirdad S. Determinants of tuberculin sensitivity in a child population covered by mass BCG vaccination. Tuber Lung Dis 1992;73:94-100.
32. Snider DE Jr. Bacille Calmette Guerin vaccinations and tuberculin skin tests. JAMA 1985;253:3438-39.
33. Musoke Mudido P, Guwatudde D, Nakakeeto MK et al. The effect of bacille Calmette-Guerin vaccination at birth on tuberculin skin test reactivity in Ugandan children. Int J Tuberc Lung Dis 1999;3: 891-95.
34. Wilson ME, Fineberg HV, Colditz GA. Geographic latitude and the efficacy of bacillus Calmette-Guerin vaccine. Clin Infect Dis 1995;20:982-91.
35. Valdespino JL, Garcia ML, Conde C et al. Misleading low HIV prevalences in concentrated epidemics. The case of Mexico (Abstract) [ThPeC7447] Abstracts of the 14th International AIDS Conference, 2002 July 7-12, Barcelona, Spain, 2002.
36. Consejo Nacional de Vacunación. Memoria. 1990-1994. Mexico: Secretaría de Salud, 1994.
37. Menzies R. Tuberculin skin testing. In: Reichman LB, Hershfield ES (eds). Tuberculosis. A Comprehensive Approach. New York: Marcel Dekker Inc, 2000, pp 279-322.
38. Comstock GW, Hammes LM, Pio A. Isoniazid prophylaxis in Alaskan boarding schools. A comparison of two doses. Am Rev Respir Dis 1969;100:773-79.
39. Mount FW, Ferebee SH. Preventive effects of isoniazid in the treatment of primary tuberculosis in children. N Engl J Med 1961;265:713-21.
40. Ministerio de Salud y Desarrollo Social. Norma Oficial del Programa Nacional de Tuberculosis. Revisión 1.998, Venezuela. Available at: http://www.sovetorax.org/avances_tuberculosis.htm. (Accessed July 13, 2005.)
41. Guia de Tuberculose: O que é, como detectar, como tratar. Ministério da Saúde. Available at: http://portalweb01.saude.gov.br/saude/buscar.cfm. (Accessed August 12, 2005.)
42. Ministerio de Salud y Acción Social. República Argentina. 1999 Guía para el diagnóstico y tratamiento de la tuberculosis en adultos. Available at: http://www.anlis.gov.ar/acrobat/normare3.pdf. (Accessed August 5, 2005.)
43. Tuberculosis Coalition for Technical Assistance. International Standards for Tuberculosis Care (ISTC). The Hague: Tuberculosis Coalition for Technical Assistance, 2006.